BRKR
Bruker Corporation
BRKR has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BRKR overall, supported by stronger fundamentals.
BRKR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Weak |
BRKR's cash flow is currently healthy, and its revenue is stable, but its profitability and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BRKR PE Valuation
BRKR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BRKR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect BRKR's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over BRKR on the outlook, with more favorable revenue expectations.
BRKR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.34 | — |
| Q3 2026 | -$1.10 | -$0.94 |
| Q2 2026 | -$0.70 | -235% |
| Q1 2026 | -$0.24 | -146% |
| Q4 2025 | -$0.15 | -120% |
| Q3 2022 | $1.82 | +3.4% |
| Q2 2022 | $1.80 | +17% |
| Q1 2022 | $1.85 | +40% |
| Q4 2021 | $1.81 | +77% |
BRKR lost $1.10 per share over the past year, and its loss has widened in each of the last three quarters.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BRKR on earnings quality, reporting a profit while its opponent remains loss making.
BRKR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $874M | +1.6% |
| Q2 2026 | $838.5M | +5.2% |
| Q1 2026 | $823.4M | +2.7% |
| Q4 2025 | $977.2M | -0.2% |
| Q3 2025 | $860.5M | -0.5% |
| Q2 2025 | $797.4M | -0.4% |
| Q1 2025 | $801.4M | +11% |
| Q4 2024 | $979.6M | +15% |
BRKR's revenue grew through 2024 and has held roughly level since: $874M last quarter, up 1.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | -4.4 points |
| Q2 2026 | -7.8% | -9.3 points |
| Q1 2026 | 1.2% | -2.7 points |
| Q4 2025 | 7.8% | +0.4 points |
| Q3 2025 | -6% | -14 points |
| Q2 2025 | 1.5% | -4.5 points |
| Q1 2025 | 4% | -5 points |
| Q4 2024 | 7.4% | -4.7 points |
BRKR's operating margin was −10% last quarter, down 4.4 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BRKR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over BRKR on profitability, with a higher operating margin.
BRKR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $96.7M | +$150.8M |
| Q2 2026 | -$106.2M | +$42.6M |
| Q1 2026 | $47M | +21% |
| Q4 2025 | $207.2M | +35% |
| Q3 2025 | -$54.1M | -1033% |
| Q2 2025 | -$148.8M | -$125.3M |
| Q1 2025 | $39M | +9650% |
| Q4 2024 | $153.3M | -12% |
BRKR's free cash flow has turned positive again: $245M over the past year, against −$11M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BRKR on cash flow, with more consistent year-over-year improvement.
BRKR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +200K shares |
| 1 year | +0.5% | +700K shares |
| 3 years | -1.9% | -2.9M shares |
BRKR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $10M |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BRKR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 10.0x | High |
| Q2 2026 | 8.2x | High |
| Q1 2026 | 5.6x | High |
| Q4 2025 | 5.4x | High |
| Q3 2025 | 6.2x | High |
| Q2 2025 | 5.9x | High |
| Q1 2025 | 4.6x | High |
| Q4 2024 | 4.4x | High |
BRKR's net debt is about 10 years of its operating earnings (EBITDA), up from 6.2 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over BRKR on leverage, with a lower net debt burden relative to earnings.
BRKR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.3 | Neutral |
| Stochastic | 52.9 | Neutral |
BRKR's weekly RSI is 55 (neutral) and its Stochastic is 53 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BRKR PE vs Healthcare Sector
| Metric | BRKR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BRKR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BRKR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $59.7 | 1.1% above |
| 20 week MA | $59.1 | 2.1% above |
| 50 week MA | $50.4 | 20% above |
| 100 week MA | $46.4 | 30% above |
| 200 week MA | $58.3 | 3.6% above |
BRKR has climbed back above all five of its weekly moving averages, and it's now 3.6% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
BRKR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.0 | $54.3 | +6.6% |
| 2021 | $54.3 | $80.3 | +48% |
| 2022 | $80.3 | $66.5 | -17% |
| 2023 | $66.5 | $73.5 | +10% |
| 2024 | $73.5 | $58.4 | -21% |
| 2025 | $58.4 | $48.0 | -18% |
| 2026 YTD | $48.0 | $60.3 | +26% |
BRKR has finished lower in three of the last six years. It's up 26% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BRKR on returns for 2026, with the stronger performance.